Cite
MLA Citation
Gerard Morton et al.. “Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy.” Radiotherapy and oncology, vol. 122, no. 1, n.d., pp. 87–92. http://access.bl.uk/ark:/81055/vdc_100041287731.0x000050